Work

The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression

Year: 2025

Type: article

Abstract: AIMS/INTRODUCTION: Few studies have assessed whether dynamic kidney function prior to sodium-glucose cotransporter-2 inhibitor (SGLT2i) initiation influenced subsequent renal outcomes. Thus, the study aimed to investigate whether combining estimated glomerular filtration rate (eGFR) slope and urinary albumin/creatinine ratio (UACR) change prior to using SGLT2i contributes to subsequent kidney outcomes. MATERIALS AND METHODS: /year and a UACR increase of 30%. The primary study outcomes included a >30% eGFR decline with a drop in eGFR categories and a >43% UACR increase with progression in UACR categories. RESULTS: After SGLT2i treatment, compared with the non-progressive renal function group, the glomerular injury group significantly lowered the risk of eGFR decline (adjusted hazard ratio [95% CI] 0.384 [0.199, 0.740]) and UACR progression (adjusted hazard ratio [95% CI] 0.514 [0.313, 0.846]). In addition, for those with a major eGFR decline before starting SGLT2i, significant improvements in the eGFR slope (P < 0.05) were observed after the treatment, irrespective of UACR increase. CONCLUSIONS: Early initiation of SGLT2i among type 2 diabetes patients with low-risk renal disease progression and glomerular injury renal status may prevent them from progressing into chronic kidney disease.

Source: Journal of Diabetes Investigation

DOI: 10.1111/jdi.70180

Authors: Yen‐Chen Chiu, Wanchana Singhan, Surarong Chinwong, Dujrudee Chinwong, Shang‐Jyh Hwang, Yaw‐Bin Huang

Institutions: Kaohsiung Medical University, Chiang Mai University, Kaohsiung Medical University Chung-Ho Memorial Hospital

Language: English

Topic: Chronic Kidney Disease and Diabetes

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,850